Real-Life Analysis Evaluating 1000 N0/Nlmi Estrogen Receptor (ER)+ Breast Cancer Patients for Whom Treatment Decisions Incorporated the 21-Gene Recurrence Score (RS) Result: Clinical Outcomes with Median Follow Up of 9 Years

Salomon M. Stemmer, MD
Head, Research Unit, Institute of Oncology
Davidoff Center, Rabin Medical Center